Fibrates in CVD: a step towards personalised medicine.

نویسنده

  • Bart Staels
چکیده

THE LANCET® is a registered trademark of Elsevier Properties S A, used under licence. International Advisory Board Karen Antman (Boston) Valerie Beral (Oxford) Robert Beaglehole (Auckland) Anthony Costello (London) Robert Fletcher (Boston) Suzanne Fletcher (Boston) Karen Gelmon (Vancouver) David Grimes (Durham) Ana Langer (Mexico City) Judith Lumley (Melbourne) Elizabeth Molyneux (Blantyre) Christopher Murray (Boston) Alwyn Mwinga (Lusaka) Marie-Louise Newell (Somkhele) Magne Nylenna (Oslo) Peter Piot (Geneva) Stuart Pocock (London) Giuseppe Remuzzi (Bergamo) Caroline Savage (Birmingham) Ken Schulz (Chapel Hill) Frank Shann (Melbourne) Jan Vandenbroucke (Leiden) Cesar Victora (Pelotas) Nick White (Bangkok) See www.thelancet.com for WebExtra content Peer reviewed and fast-tracked to publication in 4 weeks

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Riboflavin Lowers Blood Pressure: A Review of a Novel Gene-nutrient Interaction

Hypertension, defined as a systolic/diastolic blood pressure of 140/90 mmHg or greater, is estimated to carry a three-fold increased risk of developing cardiovascular diseases (CVDs). Evidence from genome-wide association studies has identified an association between blood pressure and the gene encoding the folate-metabolising enzyme, methylenetetrahydrofolate reductase (MTHFR). Recent meta-ana...

متن کامل

Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid

Cardiovascular disease (CVD) represents the leading cause of mortality worldwide. Lifestyle modifications, along with low-density lipoprotein cholesterol (LDL-C) reduction, remain the highest priorities in CVD risk management. Among lipid-lowering agents, statins are most effective in LDL-C reduction and have demonstrated incremental benefits in CVD risk reduction. However, in light of the resi...

متن کامل

Nutrigenetics and CVD: what does the future hold?

CVD is a common killer in both the Western world and the developing world. It is a multifactorial disease that is influenced by many environmental and genetic factors. Although public health advice to date has been principally in the form of prescribed population-based recommendations, this approach has been surprisingly unsuccessful in reducing CVD risk. This outcome may be explained, in part,...

متن کامل

Current Genomics in Cardiovascular Medicine

Cardiovascular disease (CVD) is a heterogeneous, complex trait that has a major impact on human morbidity and mortality. Common genetic variation may predispose to common forms of CVD in the community, and rare genetic conditions provide unique pathogenetic insights into these diseases. With the advent of the Human Genome Project and the genomic era, new tools and methodologies have revolutioni...

متن کامل

Residual Cardiovascular Risk in Diabetic Patients: the Role of Fibrate/statin Combination

Patients with Type 2 diabetes mellitus (T2DM) have increased cardiovascular disease (CVD) risk. The use of statins significantly reduces the rate of CVD events but many T2DM patients, especially those with mixed dyslipidaemia (MD), have residual CVD risk. The use of fibrates, which improve triglyceride and high-density lipoprotein cholesterol levels, is beneficial for the treatment of patients ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Lancet

دوره 375 9729  شماره 

صفحات  -

تاریخ انتشار 2010